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Abstract
Background Patients with Lynch syndrome (LS) are at an
increased risk of developing gastric cancer. In 2010, a
guideline that recommended to screen all patients for
Helicobacter pylori was implemented in the Netherlands.
H. pylori is an important risk factor in the development of
gastric cancer in the general population, and eradication of
the bacterium reduces this risk. We aimed to assess the pro-
portion of LS patients being tested and the yield and also
addressed the question whether H. pylori infection is more
prevalent in LS families with known cases of gastric cancer.
Methods Proven mutation carriers from five different Dutch
hospitals were included. The implementation of H. pylori
screening and its outcome was examined. The observation
period was 2008–2013. The presence of first-degree family
members with gastric cancer was noted, and it was observed
if H. pylori infection was more prevalent in Lynch families
with known cases of gastric cancer. Obtainable endoscopy
reports were reviewed.
Results Four hundred forty-three (male, 184) provenmutation
carriers were included. The proportion of patients screened
increased after 2010, from 37 to 68 %. Twenty percent of
the patients were infected. The 25 patients who had a first-
degree family member with gastric cancer did not have a
higher infection rate. In 30 % of cases, an endoscopy was
performed; in four patients, intestinal metaplasia and in eight
patients, gastric cancer was found.
Conclusion The recommendation to screen for H. pylori is
increasingly followed. The prevalence of infection in this pa-
tient group does not differ from the general population.
Patients who had a first-degree family member with gastric
cancer did not have a higher infection rate.
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Introduction
Lynch syndrome (LS) is an autosomal dominantly inherited
syndrome, caused by germ-line mutations in one of the four
mismatch repair (MMR) genes (MLH1, MSH2, MSH6,
PMS2) or epigenetic inactivation of MSH2 through an
EpCAM mutation [1]. Patients with LS are at an increased
risk of developing cancer, particularly colorectal cancer and
endometrial cancer. Cancers of the stomach, small intestine,
liver, gallbladder ducts, upper urinary tract, brain, and skin are
observed more frequently as well [2–4].
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Equivalent Helicobacter pylori infection rates in Lynch syndrome
mutation carriers with and without a first-degree relative
with gastric cancer
The lifetime risk of gastric cancer is estimated between 2
and 13 % for LS patients. The 5-year survival rate for gastric
cancer is only 15 % [5]. There is no evidence for clustering of
gastric cancer within specific families [2, 6, 7]. The risk ap-
pears to be highest for MLH1 and MSH2 mutation carriers.
The mean age of diagnosis of gastric cancer is 56 years.
Higher risks are reported in countries that have other risk
factors for gastric cancer such as high incidence of
Helicobacter pylori infection. This indicates that environmen-
tal factors also play a role in the development of gastric cancer
in gene carriers [8].
Intestinal-type adenocarcinoma is reported in 73–79 % of
gastric cancer cases in patients with LS [6, 9]. This type of
cancer is strongly associated with environmental factors, es-
peciallyH. pylori infection. Patients with H. pylori-associated
chronic gastritis may develop atrophy of the gastric mucosa,
followed by intestinal metaplasia. Eventually, adenocarcino-
ma of the ‘intestinal’ type can arise [10].H. pylori is classified
by the WHO as a group one carcinogen [11]. In contrast,
diffuse-type adenocarcinoma is not known to be associated
with environmental factors. This type of cancer is notoriously
difficult to detect in its early stages.
In 2013, a group of European experts (the Mallorca group)
published its revised guidelines for the clinical management of
Lynch syndrome [12]. In light of the relatively low risk of
gastric cancer and the lack of established benefits, they did
not recommend endoscopic surveillance of the upper
gastrointestinal (GI) tract. However, they recommended to
screen MMR mutation carriers for the presence of H. pylori
infection and to perform subsequent eradication. For Dutch
physicians, the recommendation to screen for H. pylori had
already been operative since 2010 [13].
To date, there are no data on the results of this recommen-
dation. The aims of the present study were to assess (1) the
proportion of LS patients being tested for H. pylori infection,
(2) the yield ofH. pylori screening, and (3) the results of upper
GI endoscopy if performed. We also address the question
whether H. pylori infection is more prevalent in Lynch fami-
lies with known cases of gastric cancer.
Material and methods
In this retrospective observational cohort study, we exam-
ined the medical records of Lynch patients from five Dutch
hospitals. Patients were eligible for inclusion if they were
proven mutation carriers. The observation time was from
December 2008 until December 2013. The study was ap-
proved by the ethics committees of the respective centers.
The implementation of H. pylori screening, the type of test
(serology, rapid urease test), urea breath test (UBT), stool
antigen test or histology and its outcome were examined
within the observation period. No data was available on the
specific type of H. pylori strain. Unfortunately, due to the
retrospective nature of the study, it was impossible to dis-
cern if the test was undertaken for screening purposes or
due to the presence of symptoms. However, we assume
that in the vast majority of the patients, the test was done
for screening purposes. The presence of first-degree family
members with gastric cancer was evaluated; the reports of
upper GI endoscopy were collected and reviewed. Patients
were excluded in case of incomplete medical records, i.e.,
if two major parameters were unknown.
Results
Baseline characteristics
In total, the medical records of 443 (male, 184) proven muta-
tion carriers were reviewed. The mean age was fifty-three
(range, 22–90 years). Twenty-three patients had died. There
were almost equally as many MLH1, MSH2, and MSH6 mu-
tation carriers (Table 1).
H. pylori screening
Screening for H. pylori was performed in 206 mutation car-
riers (46%). A total of forty-two (20%) patients were found to
be infected. Serological testing was performed most often. For
three mutation carriers, the type of test that was performed
could not be determined (Table 2).Of the patients ascertained
to be mutation carriers before 2010, 37 % was screened for
H. pylori. After 2010, the percentage increased to 68 %. The
percentage of mutation carriers screened varied across the five
different hospitals, from 68 to 37 %.
Table 1 Baseline characteristics of all mutation carriers
Characteristic Total, n Percentage Gastric cancer, n
All 443 8
Gender
Male 184 42 5
Female 258 58 4
Alive
Yes 421 95 5
No 22 5 4
Mutation status
MLH1 125 28 1
MSH2 140 32 6
MSH6 128 29 1
PMS2 34 8 –
EpCAM 16 4 –
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Gastric cancer
Only eight (1.8 %) of 443 mutation carriers were diagnosed
with gastric cancer. The mean age at diagnosis was sixty-four
(range, 51–84 years). Four of eight patients had died, all with-
in one year of diagnosis. Four patients were still alive after a
follow-up of one to eleven years after treatment. Five patients
with gastric cancer were MSH2 mutation carriers, one of
whom developed diffuse-type gastric cancer. Seven patients
were screened for H. pylori: three by serology and four by
histology. One patient was found to be infected. Only one
patient had a positive family history for gastric cancer.
Family history (first degree)
For 356 mutation carriers, the family history was available.
Twenty-five of them had at least one first-degree family mem-
ber with gastric cancer, and seven had more than one first-
degree relative with gastric cancer. The infection rate of
H. pylori in patients with a first-degree relative was 20 %,
similar to the total group. The age at diagnosis was known
for thirty-one family members; the mean age was fifty-three
(range, 16–78 years). Of the twenty-five mutation carriers
with a positive family history, twelve had an MSH2 mutation.
MSH2 mutation carriers were 1.6 times (95 % CI 0.7–4.4)
more likely to have a positive family history, when compared
to the other mutation carriers. However, this difference did not
reach statistical significance. See Table 3.
Upper endoscopy
In 132 patients (30%), upper GI endoscopy was performed. In
fifty-six cases (42 %), no abnormalities were found and no
biopsy was taken. In seventy-six patients (58 %), one or more
biopsies were taken; the results are shown in Table 4.
In 54 % of the cases, the biopsy revealed no abnormalities.
Active inflammation was the most commonly found abnor-
mality (30 %) and was seen significantly more often in H.
pylori-positive patients (OR 11.0; 95 % CI 3.1–36.0).
Intestinal metaplasia was present only in four (5 %) of the
seventy-six patients. Three of these patients were tested neg-
ative for H. pylori, using serological testing.
Discussion
This is the first study to report the outcome of H. pylori
screening in a large series of LS mutation carriers. The
study demonstrates that a substantial proportion of mutation
carriers are being tested for H. pylori. The recommendation
to screen for H. pylori has been operative since 2010, and
the proportion of patients being tested increased from 37 %
before 2010 to 68 % after 2010. However, we cannot rule
out that a small percentage of the tests was performed for
complaints instead of for screening purposes. Serology and
histology were the tests most commonly used. In 20 % of
the mutation carriers, H. pylori infection was diagnosed, a
proportion that is similar to the general population [14, 15].
Assuming H. pylori is an important risk factor in the
development of gastric cancer in Lynch patients, we expected
to find a higher infection rate in mutation carriers with a
positive family history, as H. pylori clusters within families
[16, 17]. However, a similar percentage of 20 % in the group
mutation carriers with and without a positive family history
tested positive for H. pylori.
H. pylori is a proven carcinogen in the general population.














Stool antigen 42 19
Histology 55 24
Unknown 6 3
RET rapid urease test,UBT urea breath test
a In 16 cases, two tests were performed
Table 3 Characteristics
of patients with a
positive family history
for gastric cancer















Age of family member at diagnosis
Average 53
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Lynch syndrome is however still unknown. The fact that gastric
cancer in mutation carriers occurs more frequently in countries
with a higher prevalence of H. pylori infection coupled with
fact that the incidence of gastric cancer in Western countries
has decreased parallel to the decline of H. pylori infection,
strongly suggest an important role for this bacterium in the
carcinogenesis. There exists ample research that underlines
the cost-effectiveness ofH. pylori screening in the general pop-
ulation. A recent meta-analysis showed that even in low-
prevalence countries (America, Canada, UK, and Finland),
screening the general population for H. pylori was cost-
effective in the prevention of gastric cancer [18]. Taking into
consideration the benefit of screening the general population
for H. pylori in the prevention of gastric cancer, obviously,
screening Lynch syndrome patients would also be beneficial.
In our study population, the incidence of gastric cancer and
intestinal metaplasia was much lower than expected, only
eight of the mutation carriers had a malignancy; four patients
had intestinal metaplasia. The majority of these patients were
negative for H. pylori. Only one of eight patients with a ma-
lignancy was found positive. However, it should be noted that
using histology to search for H. pylori in the presence of
intestinal metaplasia or gastric cancer may produce a false-
negative outcome.
A Finnish study examined the value of upper GI endoscopy
surveillance in seventy-three MLH1 mutation carriers and
thirty-two mutation-negative family members [9]. It showed
a substantial proportion of precursor lesions: H. pylori infec-
tion was observed in 26 %, atrophy in 14 %, and intestinal
metaplasia also in 14 %. However, in the control group,
similar proportions were found. They concluded upper
GI endoscopy surveillance was likely not beneficial in
MLH1 mutation carriers.
The prevalence of stomach cancer in Lynch patients is low-
er in the Netherlands than in its surrounding countries. Engel
et al. reported Dutch patients to be 76 % less likely to develop
gastric cancer than German patients [19]. The cause of this
difference is unknown. We included only eight patients with
stomach cancer. This low incidence (2 %) is at least partially
attributable to the fact that the registries we used were com-
piled recently, thereby not including those patients which had
already died from stomach cancer.
It is well known that the different mutations have a different
phenotype. Various studies have observed that MSH2 muta-
tion carriers have a higher risk for gastric cancer than carriers
of the other MMR mutations [6, 12]. In our study, almost half
of the mutation carriers with a positive family history are
MSH2-positive, and of eight patients with gastric cancer, five
had an MSH2 mutation. While our sample size is too small to
make conclusions, it supports the assumption that MSH2 mu-
tation carriers are at greatest risk for gastric cancer.
In conclusion: a substantial and increasing proportion of
mutation carriers is tested for H. pylori, and a similar percent-
age of 20 % in the group mutation carriers with and without a
positive family history was tested positive. The yield of upper
GI endoscopy for finding precursor lesions for gastric cancer
is low, in accordance to previous studies. In light of the low
risk of gastric cancer and the low yield of precursor lesions,
we do not recommend regular upper GI endoscopy for any of
the MMR mutations in countries with a low prevalence of
gastric cancer. Our data do not seem to support the recommen-
dation for routine H. pylori screening in Lynch syndrome
Table 4 Patient characteristics
and results of histological
examination of biopsies in
seventy-six Lynch syndrome









All 23 4 7 1 41
Gender
Male 7 3 4 1 15
Female 16 1 3 0 26
Type of mutation
MLH1 6 2 1 – 11
MSH2 8 0 5 1 16
MSH6 7 2 1 – 13
PMS2 2 0 – – 1
Family history
Positive 4 2 1 – 6
Negative 17 2 5 1 31
Unknown 2 – 1 – 4
Hp status
Positive 15 1 1 – 6
Negative 8 3 5 1 34
Unknown – – 1 – 1
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patients. It should however be noted that the low incidence of
gastric cancer makes a type 2 statistical error likely. Therefore,
we think it is presumptuous to make any claims regarding the
effectiveness of screening. To answer this question, a large
prospective randomized study would be necessary and such
a trial would be unethical in a population at an increased risk
of gastric cancer. Therefore, we recommend to continue
H. pylori screening in Lynch syndrome patients.
Compliance with ethical standards The study was approved by the
ethics committees of the respective centers.
References
1. Lynch HT, de la Chapelle A (2003) Hereditary colorectal cancer. N
Engl J Med 348:919–32
2. AarnioM, Sankila R, Pukkala E et al (1999) Cancer risk inmutation
carriers of DNA-mismatch-repair genes. Int J Cancer 12:214–8
3. Koornstra JJ, Mourits MJ, Sijmons RH et al (2009) Management of
extracolonic tumours in patients with Lynch syndrome. Lancet
Oncol 10:400–8
4. Maul JS,Warner NR, Kuwada SK et al (2006) Extracolonic cancers
associated with hereditary nonpolyposis colorectal cancer in the
Utah Population Database. Am J Gastroenterol 101:1591–1596
5. Aarnio M, Salovaara R, Aaltonen LA et al (1997) Features of gas-
tric cancer in hereditary non-polyposis colorectal cancer syndrome.
Int J Cancer 21:551–5
6. Capelle LG, Van Grieken NC, Lingsma HF et al (2010) Risk and
epidemiological time trends of gastric cancer in Lynch syndrome
carriers in the Netherlands. Gastroenterology 138:487–492
7. Watson P, Vasen HF, Mecklin JP et al (2008) The risk of extra-
colonic, extra-endometrial cancer in the Lynch syndrome. Int J
Cancer 123:444–449
8. Park YJ, Shin KH, Park JG (2000) Risk of gastric cancer in hered-
itary nonpolyposis colorectal cancer in Korea. Clin Cancer Res 6:
2994–8
9. Renkonen-Sinisalo L, Sipponen P, Aarnio M et al (2002) No sup-
port for endoscopic surveillance for gastric cancer in hereditary
non-polyposis colorectal cancer. Scand J Gastroenterol 37:574–7
10. Correa P (1992) Human gastric carcinogenesis: a multistep and
multifactorial process—First American Cancer Society Award
Lecture on Cancer Epidemiology and Prevention. Cancer Res 52:
6735–6740
11. IARC Working Group on the Evaluation of Carcinogenic Risks to
Humans (1994) Schistosomes, liver flukes, and Helicobacter pylori.
IARC Monogr Eval Carcinog Risks Hum June 61:1–241
12. Vasen HF, Blanco I, Aktan-Collan K et al (2013) Revised guide-
lines for the clinical management of Lynch syndrome (HNPCC):
recommendations by a group of European experts. Gut 62:812–23
13. 13) www.oncoline.nl, erfelijke tumoren, Lynch syndrome,
consensus based, 1-7-2010
14. Numans ME, DeWit NJ, Dirven JAM et al (2013) NHG-standaard
Maagklachten(Derde herziening). Huisarts Wet 56:26–35
15. Blankenstein V, van Vuuren L et al (2013) The prevalence of
Helicobacter pylori infection in the Netherlands. Scand J
Gastroenterol 48(7):794–800
16. Demirel BB, Akkas BE, Vural GU (2013) Clinical factors associ-
ated with H. pylori infection—is there an association with gastric
cancer history in first-degree family members? Asian Pacific J
Cancer Prev 14:1797–1802
17. Rokkas T, Sechopoulos P, Pistiolas D et al (2010) H. pylori infec-
tion and gastric histology in first-degree relatives of gastric cancer
patients: a meta-analysis. Eu J Gastroen Hepat 22:1128–1133
18. Lansdorp-Vogelaar I, Sharp L (2013) Cost-effectiveness of screen-
ing and treating H. pylori for gastric cancer prevention. Best Pract
Res Clin Gastroenterol 27:933–947
19. Engel C, Loeffler M, Steinke V et al (2012) Risks of less common
cancers in proven mutation carriers with Lynch syndrome. J Clin
Onc 30:4409–4415
Int J Colorectal Dis (2016) 31:693–697 697
